Case Study: Pfizer’s Lyrica’s patent extension with paediatric exclusivity
USFDA granted 6-month pediatric exclusivity to Lyrica, which helps to Lyrica to extent the patent expiration by additional 6 month. Lyrica received... Read More
Allena’s oxalate decarboxylase to treat paediatric hyperoxaluria gets US FDA orphan drug status
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercialising innovative, non-systemic, oral protein therapeutics to treat metabolic and orphan... Read More